Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials
19 Setembro 2023 - 10:00AM
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing
and precision medicine, today announced two key milestones in its
strategic partnership with Illumina Inc. (NASDAQ: ILMN), a global
leader in DNA sequencing and array-based technologies, to advance
and support clinical research for gene-based, targeted therapies.
Under the strategic partnership, Myriad and Illumina are working
together to advance comprehensive genomic profiling plus homologous
recombination deficiency (HRD) testing using the globally
distributed Illumina TruSight Oncology 500 (TSO 500) assay, which
enables comprehensive genomic profiling by analyzing 523 genes
across DNA and RNA variants.
The first milestone achieved qualifies Myriad to conduct
prospective clinical trial testing with an investigational use only
test based off of Illumina’s in-development IVD solution, TruSight
Oncology Comprehensive test (TSO Comp). This positions Myriad to
partner with leading pharmaceutical companies and academic
institutions to further development of companion diagnostics.
The second milestone involves Myriad’s initiation of its first
reproducibility test project to support future regulatory filings
for TSO Comp. Myriad now provides support in Illumina’s
partnerships with pharmaceutical companies to develop companion
diagnostics on TSO Comp.
“These key milestones empower Myriad to accelerate the pace of
research and scientific innovation to support the advancement of
cancer care for patients,” said Paul Bartel, senior vice president
of companion diagnostics, Myriad Genetics. “Through our
partnership, we are leveraging Myriad’s MyChoice CDx HRD technology
with Illumina’s expertise in comprehensive genomic profiling to
broaden clinical research opportunities and drive CDx development
for gene-based therapies.”
"Myriad is a key strategic partner in delivering clinically
relevant answers with TSO," said Kevin Keegan, vice president and
head of Illumina’s Oncology Business Unit. "We are thrilled that
Myriad recognizes the importance and value of Illumina’s TruSight
Oncology portfolio and shares our excitement for the potential to
incorporate HRD testing globally."
About Myriad GeneticsMyriad Genetics is a
leading genetic testing and precision medicine company dedicated to
advancing health and well-being for all. Myriad develops and offers
genetic tests that help assess the risk of developing disease or
disease progression and guide treatment decisions across medical
specialties where genetic insights can significantly improve
patient care and lower healthcare costs. For more information,
visit www.myriad.com.
Safe Harbor Statement This press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, including that
the company’s partnership with Illumina will broaden clinical
research opportunities and drive CDx development for gene-based
therapies.. These “forward-looking statements” are management’s
expectations of future events as of the date hereof and are subject
to known and unknown risks and uncertainties that could cause
actual results, conditions, and events to differ materially and
adversely from those anticipated. Such factors include those risks
described in the company’s filings with the U.S. Securities and
Exchange Commission, including the company’s Annual Report on Form
10-K filed on March 1, 2023, as well as any updates to those risk
factors filed from time to time in the company’s Quarterly Reports
on Form 10-Q or Current Reports on Form 8-K. Myriad is not under
any obligation, and it expressly disclaims any obligation, to
update or alter any forward-looking statements, whether as a result
of new information, future events or otherwise except as required
by law.
Media ContactGlenn Farrell(385)
318-3718PR@myriad.com
Investor ContactMatt Scalo(801)
584-3532IR@myriad.com
Illumina (NASDAQ:ILMN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Illumina (NASDAQ:ILMN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024